- Home
- AENT vs CRDF Comparison
AENT vs CRDF Comparison
Compare AENT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- CRDF
- Stock Information
- Founded
- AENT 1990
- CRDF 1999
- Country
- AENT United States
- CRDF United States
- Employees
- AENT N/A
- CRDF N/A
- Industry
- AENT Durable Goods
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AENT Consumer Discretionary
- CRDF Health Care
- Exchange
- AENT Nasdaq
- CRDF Nasdaq
- Market Cap
- AENT 148.0M
- CRDF 196.2M
- IPO Year
- AENT N/A
- CRDF N/A
- Fundamental
- Price
- AENT $2.40
- CRDF $2.63
- Analyst Decision
- AENT
- CRDF Strong Buy
- Analyst Count
- AENT 0
- CRDF 4
- Target Price
- AENT N/A
- CRDF $12.00
- AVG Volume (30 Days)
- AENT 39.4K
- CRDF 1.1M
- Earning Date
- AENT 05-12-2025
- CRDF 05-20-2025
- Dividend Yield
- AENT N/A
- CRDF N/A
- EPS Growth
- AENT N/A
- CRDF N/A
- EPS
- AENT 0.13
- CRDF N/A
- Revenue
- AENT $1,070,804,000.00
- CRDF $683,000.00
- Revenue This Year
- AENT $4.77
- CRDF N/A
- Revenue Next Year
- AENT N/A
- CRDF N/A
- P/E Ratio
- AENT $17.32
- CRDF N/A
- Revenue Growth
- AENT N/A
- CRDF 39.96
- 52 Week Low
- AENT $1.10
- CRDF $2.01
- 52 Week High
- AENT $11.57
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- AENT 37.62
- CRDF 41.22
- Support Level
- AENT $2.31
- CRDF $2.42
- Resistance Level
- AENT $2.67
- CRDF $2.87
- Average True Range (ATR)
- AENT 0.32
- CRDF 0.18
- MACD
- AENT -0.02
- CRDF 0.01
- Stochastic Oscillator
- AENT 16.02
- CRDF 24.42
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.